In vitro studies of the proliferation of myeloid progenitor cells are often used to develop an understanding of the nature of myeloid diseases in patients. A direct comparison of the proliferative ability of MDS progenitors and their in vivo proliferative capacity, as indicated by marrow cellularity, demonstrated a significant discordance. This is especially true for erythroid progenitors since the in vitro proliferation of these cells is severely compromised despite the presence of erythroid hyperplasia in vivo. Studies of the effects of various changes in the in vitro culture conditions have demonstrated that the proliferation marrow progenitors can indeed be improved strongly suggesting that the apparent reduction in MDS progenitor cells in MDS is not real but is a consequence of the use of in vitro conditions which support the proliferation of normal progenitor cells while being suboptimal for MDS progenitors.
|Number of pages||15|
|Journal||Cancer Research Therapy and Control|
|Publication status||Published - 17 Mar 1999|
- In vitro